Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 12;14(4):665-669.
doi: 10.1016/j.dsx.2020.05.023. Online ahead of print.

Convalescent Plasma: A Possible Treatment Protocol for COVID- 19 Patients Suffering From Diabetes or Underlying Liver Diseases

Affiliations
Free PMC article

Convalescent Plasma: A Possible Treatment Protocol for COVID- 19 Patients Suffering From Diabetes or Underlying Liver Diseases

Ashish Yashwantrao Pawar et al. Diabetes Metab Syndr. .
Free PMC article

Abstract

Background & aim: As on date, no specific treatment is available for devastating COVID-19 (SARS-CoV-2) infection. This pandemic viral infection has affected over 200 countries within a very short time and created a calamitous situation across the globe. As per WHO guidelines, the treatment is mainly symptomatic and supportive. This clinical protocol has not proven sufficient to save the lives of COVID-19 patients suffering from diabetes or having underlying liver diseases; hence there is utmost need to tackle this situation by other means such as Convalescent Plasma (CP) therapy.

Methods: A comprehensive literature survey was carriedout using Elsevier, PubMed, Taylor & Francis, Springer, Nature and Google search engines.

Results: The patients suffering from diabetes or liver dysfunction or any other underlying diseases are at greatest risk of SARS-CoV-2 infection. From the study, it is proved that plasma collected from the recovered patients of viral infection has considerable potential to treat the viral disease without the occurrence of adverse effects.

Conclusion: The CP therapy can be a possible life saving alternative to treat critical COVID-19 patients having diabetes or underlying liver dysfunction. Hence, randomised clinical trials are recommended at the earliest to save the lives of infected individuals of COVID-19.

Keywords: ACE2; COVID-19; Convalescent plasma; Diabetes; Liver diseases; Neutralizing Antibodies; SARS-CoV-2.

Conflict of interest statement

Declaration of competing interest The authors declare that they have no competing interests.

Figures

Image 1
Fig. 1
Fig. 1
Schematic mechanism of neutralizing antibodies. Neutralizing antibodies binds with Receptor bonding domain (RBD) of the SARS-CoV-2 Spike protein and inhibits the binding of RBD to ACE2 receptor as shown in the figure. The protruding portion (blue colour) highlights the antibody epitope. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
Fig. 2
Fig. 2
Schematic representation of Passive antibody therapy for COVID -19 patients highlighting the major steps.

Similar articles

See all similar articles

References

    1. Zhou P., Yang X.L., Wang X.G., Hu B., Zhang L., Zhang W. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020 Feb 3 doi: 10.1038/s41586-020-2012-7. [Epub ahead of print] - DOI
    1. https://www.worldometers.info/coronavirus/?
    1. International Diabetes Federation IDF diabetes atlas. 2019. https://www.diabetesatlas.org/en/ 9th edn. Brussels, Belgium.
    1. Ruan Q., Yang K., Wang W., Jiang L., Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020 Mar 3 doi: 10.1007/s00134-020-05991-x. - DOI
    1. Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention. J Am Med Assoc. 2020 Feb 24 doi: 10.1001/jama.2020.2648. - DOI
Feedback